Patient compliance and persistence with recommended drug therapy remains a significant issue across treatment categories. Improving compliance and persistence can lead to better health outcomes and incremental brand growth. To improve this behavior, we must examine the underlying demographic factors and attitudes towards treatment of chronic ailments, both symptomatic and asymptomatic.

This research by Ipsos Insight Health defines the attitudinal and behavioral drivers of class persistence and complaince among representative sample of U.S. adults.